Replies to post #171024 on Biotech Values

[iwfal]

GERN -

It seems to me time to first response were similar, 6, 13 weeks for arm A; 6, 12, 12 weeks for arm B.

I wasn't particularly clear, but I was counting all responses (i.e. everything they labeled on the graphs) and by week 12 of Arm A they had only 2 patients with a response marked (a PR and a Spleen CI), whereas Arm B had 6. Not entirely independent of the total % response - but some additional confirmation that the more aggressive dosing provides real benefit.

They do have concern about weekly dosing in MF though as grade 3/4 neutropenia, thrombocytopenia, anemia much higher in arm B than A.

Agreed that they probably can't get much more aggressive on dosing - but quick look through other chemos says that the hematological SAE are probably within family of approved doses of other chemo agents (I'd have to do more than a quick glance to really know better - e.g. Jevtana has worse neutropenia and worse Leukopenia - but better thrombocytopenia. And I don't know how the different 'penias detrimentally synergize.)